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SGLT2i in HFrEF

SGLT2 Inhibitors in the Management of
Heart Failure with Reduced Ejection Fraction
Susannah Jackson, PA-S & Meghan Mathis, PA-S
James Madison University Physician Assistant Program

Abstract
Objective: to assess whether SGLT2 inhibitors significantly reduce the risk of hospitalization for
heart failure (HAHF) and cardiovascular death in patients with heart failure with reduced ejection
fraction (HFrEF). Design: systematic literature review. Methods: searches were conducted in
PubMed with the terms !SGLT2 Inhibitors,” “heart failure with reduced ejection fraction (HFrEF),”
and !hospitalization” and the following limits: publication within the last 5 years, clinical trials,
meta-analyses, randomized control trials, humans, and English. These criteria determined the
selected literature: randomized control trial (RCT), use of an SGLT2i compared to placebo, and
outcomes including HAHF and/or cardiovascular related death. Results: DAPA-HF: 27% RRR
in HAHF, 23% RRR of composite decrease for HAHF and cardiovascular death. NNT =
21(HAHF). EMPORER-REDUCED: 28% RRR in HAHF, 20% RRR composite decrease for
HAHF and cardiovascular death. NNT = 19 (HAHF). CANVAS: 33% RRR of HAHF and 22%
RRR for composite outcome of cardiovascular death and HAHF. NNT = 31 (HAHF).
Conclusion: SGLT2is modestly reduced HAHF and cardiovascular death in HFrEF patients and
may be an appropriate secondary adjunct to standard treatment for secondary prevention of
HAHF and cardiovascular causes of death.

Introduction
Recent medical research has shown that SGLT2i reduce HAHF and improve mortality.
Heart failure is a common diagnosis in the US: between 2011 - 2014, 6.5 million Americans had
HF1. This growing number is projected to grow to more than 8 million HF patients by 2030.
Treating HF is expensive; total treatment in 2012 cost $30.7 billion,1 and treatment in 2030 is
projected to cost $69.7. HAHF is a significant cost of treatment.
Death and remodeling of the heart cause HF, which is categorized into diastolic HF or
HFpEF, and systolic HF or HFrEF. Patients with Type II Diabetes Mellitus (T2DM) are at
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increased risk for developing HF. SGLT2i (canagliflozin, dapagliflozin, and empagliflozin) are
new T2DM drugs that inhibit glucose reabsorption in the kidney. A 2015 RCT unexpectedly
showed that empagliflozin reduced the relative risk (RR) for HAHF by 35%, and this sparked
research on SGLT2i in HF.3 Currently, the mechanism by which SGLT2i improve HF outcomes is
not understood. However, the emerging data show that SGLT2i improve HFrEF outcomes
regardless of T2DM. This review discusses whether SGLT2i decrease HAHF and all-cause
mortality in HFrEF.

Clinical Question
A.M. is a 65-year-old female with a history of hypertension (HTN), coronary artery
disease (CAD), and a recent myocardial infarction (MI). She has HFrEF and her left ventricular
ejection fraction (LVEF) is 30%. Would prescribing an SGLT2i to AM, in addition to standard
HFrEF therapy, reduce her risk of HAHF and cardiovascular death?

Methods
An initial PubMed search performed on September 15th, 2020 with search terms
!SGLT2 Inhibitors,” “heart failure with reduced ejection fraction,” and !hospitalization” yielded 88
articles. These limits reduced the number of articles to ten: publication within the last five years,
clinical trials, meta-analyses, RCT, humans, and publication in English. These inclusion criteria
resulted in three studies: RCT, use of an SGLT2i compared to placebo, and outcomes including
decreased HAHF and/or cardiovascular related death. Exclusion criteria included patients
younger than 19. A second PubMed search on October, 22nd, 2020 yielded the EMPERORREDUCED Trial, which had greater homogeneity than the DEFINE-HF and was therefore
included in place of DEFINE-HF.
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Results
Study #1 Dapagliflozin in Patients with Heart Failure and Reduced Ejection
Fraction. J.J.V. McMurray, et al.4
Objective: To evaluate Dapagliflozin"s safety and efficacy in HFrEF patients, regardless of the
presence of diabetes mellitus.
Study Design: This was a double-blind, randomized, placebo-controlled trial of 4,744 patients
with established New York Heart Association (NYHA) HFrEF. Table 1 summarizes the inclusion
and exclusion criteria.
Table 1: DAPA-HF Inclusion and Exclusion Criteria
Inclusion Criteria

Exclusion Criteria

Age > 18

Recent treatment with SGLT2i

EF < 40%

Unacceptable side effects from SGLT2i

Symptoms of NYHA Class II-IV

Type 1 diabetes mellitus

*NT-proBNP > 600pg/mL

Symptoms of hypotension or systolic blood
pressure < 95 mmHg
**eGFR < 30 ml/minute or rapidly declining
renal function

*N-terminal pro--B-type natriuretic peptide, **eGFR is estimated glomerular filtration rate
In addition to SGLT2i or placebo, all patients received standard HFrEF therapy, including
cardioverter-defibrillator or cardiac resynchronization therapy (or both), an angiotensinconverting enzyme-inhibitor (ACEi), an angiotensin receptor blocker (ARB) or sacubitrilvalsartan plus a beta blocker. Researchers encouraged additional treatment with a
mineralocorticoid receptor antagonist (MRA). All patients with DM2 were continued on their DM2
medications. Randomization was stratified by whether patients had DM2. Dapagliflozin was
given in 10mg pills daily, and the control was placebo. The primary outcome was a composite of
worsening HF or death from cardiovascular causes. Secondary outcomes included HAHF,
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cardiovascular deaths, symptom improvement, composite worsening of renal failure or renal
death, and death from any cause.
Patients were evaluated at 14 and 60 days after randomization, and then every four
months; the mean follow-up was 18.2 months. Data analysis was conducted with intention to
treat analysis (ITT), meaning all patients that were randomized were included in the analysis.
Study Results: The primary composite outcome of worsening HF or death from cardiovascular
causes occurred in 16.3% of patients who received dapagliflozin and 21.2% of patients who
received placebo (hazard ratio, 0.74; 95% CI: 0.65 to 0.85; P < 0.001). Additionally, 9.7% of
dapagliflozin patients had HAHF and 13.4% placebo patients had HAHF (hazard ratio, 0.70;
95% CI, 0.59 to 0.83). Symptom relief was quantified using the Kansas City Cardiomyopathy
Questionnaire, and patients who received dapagliflozin showed significant symptom
improvement, compared to placebo (25.3% vs. 32.9%; odds ratio (OR), 0.84, 95% CI, 0.78 to
0.90; P < 0.001). The data demonstrated a 27% relative risk reduction (RRR) for HAHF with a
number needed to treat (NNT) of 21, and a 23% RRR of composite decrease for HAHF and
cardiovascular death. Researchers hypothesized that patients with Class II HFrEF may have
experienced greater overall therapy response.
Study Critique: This study has several advantages. The number of subjects, 4,744, was large,
and few were lost to follow up or required discontinuation of dapagliflozin. There were few
exclusion criteria, and the study included 20 countries. Many researchers conducted DAPA-HF,
producing extensive subgroup analysis, including glycosylated hemoglobin, creatinine,
hematocrit, NT-proBNP, weight, and systolic BP. Additionally, several favorable and statistically
significant results were shown, as discussed in the results section above.
This study had several limitations which reduced its application to HFrEF patients. Less
than 50% of participants had eGFR < 60, which is inconsistent with the low eGFR usually seen
in HFrEF patients. Only approximately 5% of participants were African American, which is
disproportionately fewer than the number of African Americans who have HFrEF. A high
percentage of participants were male (76.6%), and the average body mass index (BMI) was
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28kg/m², reducing generalization to females and patients with BMIs > 28kg/m². Approximately
67% of patients had NYHA Class II, and the DM2 patients were likely well-controlled and
healthy, requiring only one or two DM2 medications. Lastly, this study was funded by
AstraZeneca, the manufacturer of dapagliflozin.

Study #2: Cardiovascular and Renal Outcomes with Empagliflozin in Heart
Failure (EMPEROR-REDUCED Trial). Packer et al.5
Study objective: To evaluate the efficacy of empagliflozin to treat Class II-IV HFrEF. The
primary outcome was a composite of cardiovascular death and HAHF.
Study design: This study was a double-blind, parallel-group, event-driven RCT performed in
520 centers across 20 countries. Inclusion criteria were NYHA Class II-IV HFrEF with EF 40%
or less. Patients with EF > 30% were required to have had HAHF in the past year or have a NOProBNP that indicated increased risk for serious HF event. Table 2 shows further NT-ProBNP
requirements for patients based on their EF.
Table 2: EMPEROR-REDUCED BNP Minimum Requirements by EF
Ejection Fraction

Minimum NT-ProBNP

Minimum NT-ProBNP in
Patients with Atrial Fibrillation

< 30%

600 pg/ml

1,200 pg/ml

30% - 35%

1000 pg/ml

2,000 pg/ml

36% - 40%

2500 pg/ml

5,000 pg/ml

3,730 patients were randomly assigned to receive either daily empagliflozin (1,863 patients) or
placebo. All patients were required to receive standard HF therapies (including diuretics, RAAS
blockers and neprilysin inhibitors, beta-blockers, and MRAs), and ITT analysis was used.
Study results: The hazard ratios for the effect of empagliflozin on cardiovascular death and on
the first HAHF were 0.92 and 0.69, respectively, for a composite HR of 0.75. During the trial
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period, 19 patients would need to have received empagliflozin to prevent one primary event
(95% CI, 13 to 37). Empagliflozin"s effect on the primary outcome was consistent across
prespecified subgroups, including patients with and without diabetes at baseline. Among the
patients who were receiving sacubitril–valsartan at baseline, the hazard ratio for the comparison
between empagliflozin and placebo for the primary outcome was 0.64, as compared with 0.77
among those who were not receiving sacubitril–valsartan. The total HAHF was lower among
patients receiving empagliflozin, with a HR of 0.70. Overall, the data demonstrated a 28% RRR
for HAHF with an NNT of 19, and a 20% RRR composite decrease for HAHF and
cardiovascular death. Table 3 summarizes this trial"s results.
Table 3: EMPEROR-REDUCED Results
Empagliflozin
Patients (N = 1863)

Placebo Patients
(N = 1867)

Hazard Ratio or
Absolute Risk
Difference

Primary Outcome:
Composite of HAHF
and Cardiovascular
death

361 (19.4)

462 (24.7)

0.75 (0.65 to 0.86)

HAHF

246 (13.2)

342 (18.3)

0.69 (0.59 to 0.81)

Cardiovascular death

187 (10.0)

202 (10.8)

0.92 (0.75 to 1.12)

Study critique: This was a large RCT that included several centers throughout multiple
countries. Tracking NT-ProBNP enabled the researchers to analyze results according to HFrEF
severity. All participants received standard HFrEF therapy which supports our clinical inquiry.
EMPEROR-REDUCED replicated the findings from DAPA-HF. The fact that empagliflozin, in
addition to dapagliflozin, reduced mortality indicates that the entire class of medications,
SGLT2i, may reduce mortality. Limitations included a study population of predominantly white
males and funding by Jardiance, the company that manufactures empagliflozin. Another
concern is the research was limited to measures and evaluation of secondary prevention in
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regards to HAHF. An analysis of the efficacy regarding empagliflozin in primary prevention of
cardiovascular outcomes is an area that requires further investigation.

Study #3 Canagliflozin and Cardiovascular and Renal Events in Type 2
Diabetes. Bruce Neal, M.B., et al.6
Objective: To determine how SGLT2i treat cardiovascular and renal pathologies and to
researchSGLT2i safety.
Study Design: The CANVAS Program was a composite of two RCTs, the Canagliflozin
Cardiovascular Assessment Study (CANVAS, 2009) and CANVAS-Renal (CANVAS-R, 2014).
The aim of CANVAS, which began four years before canagliflozin received FDA approval, was
to show that it was safe in terms of cardiovascular effects. CANVAS-R was designed to produce
data that would be assessed together with that from CANVAS, to meet phase four
cardiovascular safety requirements. As its name suggests, it was designed to study the drug"s
effects on renal outcomes, specifically albuminuria. In summary, the CANVAS Program, a
composite of the two sister RCTs, was intended to study canagliflozin"s effects on
cardiovascular and renal systems, and its safety profile.
The primary outcome was a composite of death from cardiovascular causes, nonfatal
MI, and nonfatal stroke. The secondary outcomes were death from any cause, death from
cardiovascular causes, progression of albuminuria, and composite of death from cardiovascular
causes and HAHF. Inclusion criteria included T2DM diagnosis (HbA1C 7-10.5%), age > 30 with
a history of symptomatic atherosclerotic cardiovascular disease (ASCVD), or > 50 with two or
more of the following: duration of diabetes for 10+ years, systolic blood pressure (SBP) >
140mmHg despite therapy with > 1 antihypertensive drugs, current smoking, micro or
macroalbuminuria, or HDL < 1. An eGFR < 30mL/min was the exclusion criterion.
CANVAS patients were randomly assigned to receive 300mg canagliflozin daily, or
matching placebo. CANVAS-R patients were randomly assigned to receive 100mg canagliflozin
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daily with the option to increase the dose to 300mg daily, or matching placebo. Patients were
continued on standard pharmacotherapy to maintain glycemic control. This study was designed
to show either cardiovascular non-inferiority or superiority. For canagliflozin compared to
placebo, a HR < 1 indicated superiority, and < 1.3 indicated cardiovascular safety.
Study Results: A significant finding from The Canvas Program was that 5.5% of patients taking
canagliflozin experienced HAHF, and 8.7% of patients taking placebo had HAHF (HR 0.67;
(0.52-0.87). Additionally, canagliflozin showed benefit across all primary and secondary
endpoints; 29.6% of patients taking canagliflozin and 31.5% of patients taking placebo
experienced a primary outcome event (death from cardiovascular cause, nonfatal MI, nonfatal
stroke). Overall, this trial demonstrated a 33% RRR of HAHF with an NNT of 31 and a 22%
RRR for composite outcome of cardiovascular death and HAHF. Other notable improvements
were across all secondary outcomes, and also with blood pressure, weight, and HbA1C levels.
Regarding safety outcomes, the data showed an increased risk of amputation of toes,
feet, or legs among patients on canagliflozin, with a HR of 1.97. [71% of these patients had their
most proximal amputation at the level of the toe or metatarsal.] Other negative outcomes higher
among patients taking canagliflozin were genital infections, volume depletion, and diabetic
ketoacidosis (DKA).
Study Critique: The Canvas Program was a powerful study with many advantages. It studied a
large number of patients, 10,142, with an extensive duration of follow-up (mean of 188.2
weeks). Furthermore, this trial considered the effects of canagliflozin in T2DM patients only, and
the mean duration of T2DM diagnosis was over 13 years, making this data applicable to the
patients who may need SGLT2i the most: diabetics.
Significant weaknesses of this trial include lack of statistical significance. Due to the
predetermined statistical hypothesis testing sequence, the primary and secondary outcomes, all
of which canagliflozin improved, were not considered statistically significant. This is a drawback
from enabling direct application to patients. Additionally, 51.6 patients per 1,000 patient years
had a HgbA1C < 8%. This tight glycemic control is hard to achieve and rare among diabetics,
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which may further restrict application of this data to real-world patients. Lastly, The Canvas
Program was funded by the producer of Invokana, the trade brand of canagliflozin, implying
possible conflict of interest. Of note, this RCT is heterogeneous to the two former RCTs, which
considered SGLT2i in patients with and without T2DM, whereas this RCT considered the effects
of canagliflozin in T2DM patients only.

Discussion
Heart failure contributes to 1 out of 8 deaths in the U.S. and is projected to increase in
incidence each year.7 While some aspects of standard therapies have proven beneficial in
regards to all-cause mortality and survival outcomes, there is room for improvement regarding
management of HFrEF patients. Recent research is focused on decreasing HAHF and
minimizing cardiovascular deaths. The aggregate data from recent RCTs suggest that adding
SGLT2i to standard HF therapy reduces mortality HAHF.8
While the outcomes of the three RCTs evaluated in this paper show a benefit with the
use of SGLT2i in patients with HFrEF independent of diabetes status, the limitations of each
study cannot be disregarded. All three studies were funded by major pharmaceutical companies
who have a vested monetary interest in demonstrating that their products treat more than just
diabetes. These medications are newer to the market and unavailable as generics, suggesting
that only the affiliated companies have funding to further their research.
One limitation of the CANVAS trial was they were not initially investigating safety
regarding cardiovascular and diabetic kidney disease (DKD), not HAHF. CANVAS investigated
empagliflozin therapy in diabetic patients only. Further limitations included the predominant
white male study populations in the DAPA-HF and the EMPEROR-REDUCED trials. A large
proportion of patients suffering from HFrEF are African American. African Americans are 20%
more likely to die from complications of heart disease when compared to Whites.9 The studies
showed a similar disconnect between proportion of female participants and HF prevalence.
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While women tend to develop HF at an older age than men, the incidence between the sexes is
similar.10
Currently, dapagliflozin (Farxiga) is the only SGLT2i with FDA approval to treat adults
with HFrEF (NYHA class II-IV).4 The use of dapagliflozin is recommended as a secondary
adjunct agent in patients with persistent symptoms and elevated NT-proBNPs, despite current
optimized standard therapy.11
Empagliflozin (Jardiance) recently obtained FDA approval to accelerate research into
whether it can improve HFrEF outcomes after MI. However, its use for this indication is currently
off-label, and costs may not be covered by insurance. Like dapagliflozin, it is indicated as an
adjunct in persistently symptomatic patients who are already optimized on other therapies and is
effective in patients with or without type 2 diabetes (Packer 2020).
Canagliflozin (Invokana) currently only has FDA approval to treat DKD and to reduce the
risk of HAHF in patients with T2DM.12 While data suggest that the entire class of SGLT2i can
improve HFrEF outcomes, further research is required for canagliflozin to receive approval in
patients without T2DM.

Approach to the Patient
Our patient is A.M., a 65-year old female with a history of HTN, CAD, an recent MI, who
now has an EF of 30%. Should we prescribe an SGLT2i in addition to the standard HFrEF
regimen? Since she was recently diagnosed, her NYHA Class is unknown, and she is naive to
standard HFrEF therapy, we do not endorse prescribing an SGLT2i at this time. While these
medications have demonstrated consistent and reproducible outcomes regarding positive
cardiovascular effects and decreased HAHF in HFrEF patients, regardless of whether or not
they have T2DM, they lack data demonstrating long-term safety, efficacy, and cost-efficiency.
To manage A.M., laboratory studies should be drawn at baseline and followed to monitor
her response to treatment. These include NT-ProBNP, BUN and creatinine, eGFR, and

10

SGLT2i in HFrEF
electrolytes, among others. A.M. should follow up two weeks after starting therapy, and her
medications should be titrated to efficacy with manageable side effects.5
If she receives a NYHA Class II - IV diagnosis and experiences persistent symptoms,
despite standard HFrEF management, we would discuss adding dapagliflozin. Before
prescribing, we would ensure her volume status was adequate, measure her blood pressure,
ensure her CrCl is > 30 ml/minan, and get a baseline NT-ProBNP and CMP. We would inform
A.M. that dapagliflozin can cause a moderate decrease in weight and blood pressure and has a
low occurrence of hypoglycemia. While using dapagliflozin with lisinopril is safe and requires no
monitoring, its combination with bumetanide may decrease its anti-diabetic effects and
precipitate a hyperglycemic state (Lexicomp). We would also notify her of the increased risk of
urinary tract infections, vulvovaginal infections, hypotension, dehydration, and fractures.

Conclusion
This paper aimed to answer the following question: among HFrEF patients, does the
addition of an SGLT2i to standard therapy reduce the risk of HAHF and cardiovascular death?
Three large RCTs have data that begin to answer this question. DAPA-HF unexpectedly showed
that SGLT2i were associated with improved cardiovascular outcomes. This novel research
prompted the EMPEROR-REDUCED and CANVAS trials to examine the data and launch
placebo-controlled trials to gather more information. Thus far, the accumulating research is
promising for the future of HFrEF therapy. Both DAPA-HF and EMPEROR-REDUCED trials
examined the effects of SGLT2i in patients with and without T2DM and showed improvements,
suggesting that this class of drugs has unknown MOAs that benefit HFrEF patients, and not
through glycemic control.
However, further research is needed. At this time, the only SGLT2i that is currently
approved for HFrEF is dapagliflozin, and only as add-on, second-line therapy. Therefore, the
current data have mainly achieved the justification of further, more conclusive and specific
research into this clinical question.Further research into this question should be focused on how
much SGLT2i benefit non-T2DM patients, and how they do this. While it is true that many
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HFrEF patients have comorbid T2DM, many do not, but could still benefit from using an SGLT2i,
pending further conclusive research.
HAHF is a negative health outcome common among HFrEF patients, and a costly
expense for American healthcare. Use of SGLT2i may alleviate this unfortunate toll on our
economy and wellbeing. While SGLT2i are still new drugs and therefore expensive, their prices
will become more manageable, as they are already becoming widely used to treat T2DM. Thus,
further research into the possible benefits of SGLT2i on HFrEF may, in time, save US healthcare
millions.
An additional, fascinating area of research is the mechanism of action (MOA) of SGLT2i
on the cardiovascular system. Currently, SGLT2i MOA on T2DM glycemic control is well
understood. However, the untapped potential of SGLT2i to reduce morbidity and mortality in
HFrEF patients will more easily become adopted and efficacious when the MOA is shown
through research. In conclusion, the use of SGLT2i may be an appropriate secondary adjunct to
standard treatment for secondary prevention of HAHF and cardiovascular causes of death.
Further research regarding long-term efficacy, safety, and cost-effectiveness is needed.
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